SAUDI ARABIA – Acino, a leading provider of high-quality pharmaceutical products and services, announced that it has formed a strategic partnership with Saudi Arabia’s Alpha Pharma.
The partnership aims to support the Kingdom’s Health Sector Transformation Programme, which was launched as part of National Vision 2030.
Closely following Acino’s recent announcement of expansion in Saudi Arabia, the agreement was formalised at a special signing ceremony, in the presence of His Excellency Abdullah Al Masoud, Saudi Commercial Attaché to Switzerland.
Also present were Steffen Saltofte, CEO, Acino; Dr. Andrew Bird, General Manager and Head of Region, Middle East, Turkey and Africa, Acino; Fahad Al Otaibi, Country Manager for Saudi Arabia, Acino.
Mr. Yaser Y. Naghi, CEO of Cigalah Health Care company and its subsidiary Alpha Pharma; and Dr. Murad Al Saggaf, General Manager, Alpha Pharma also witnessed the signing of ratification of the partnership.
“Partnerships like these are a step in the right direction towards achieving the Saudi Vision 2030 and the Health Sector Transformation Programme,” said H.E. Abdullah Al Masoud, Saudi Commercial Attaché to Switzerland.
We applaud Acino’s efforts to expand its presence in the Kingdom, as well as its striking collaborations with organizations such as Alpha Pharma to increase access to treatments for patients who need them the most.”
Saudi Arabia’s Health Sector Transformation Programme is a key component of the National Transformation Programme, with the goal of improving healthcare quality and efficiency while also improving treatment outcomes.
Acino will work with Alpha to expand its commitment to providing patients and healthcare providers with improved access to high-quality essential medicines.
The agreement between Acino and Alpha will cover a wide range of therapeutic areas, including Acino’s medications for gastro/gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), and pain management.
The products are expected to be available throughout the Kingdom in 2023.
Earlier on Alpha Pharma and subsidiary of Cigalah Healthcare Company, a leading Saudi healthcare distributor, announced a partnership with global technology firm SAP to support its digital transformation as part of a broader business strategy.
The new collaboration aims to streamline Alpha Pharma’s operations in finance, supply chain, logistics, production, and human resources, while also aligning the organization with Saudi Vision 2030’s digitization goals.
Recognizing the benefits of a digitized management approach, Alpha Pharma intends to deploy solutions such as SAP S/4HANA, SuccessFactor, Private Cloud, and RISE with SAP’s core offering to centralize and streamline a number of key business functions.
Alpha Pharma, founded in 2017, is a subsidiary of Cigalah Healthcare Company with a direct investment of SR296 million (US$78.9 million).
In accordance with international Current Good Manufacturing Practice regulations, the pharmaceutical plant has the capacity to produce up to 1 billion tablets, 300 million capsules, and 30 million bottles of syrups and suspensions per year.
In addition, the plant maintains high quality throughout the manufacturing process while focusing on continuous improvement and minimal operator intervention.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
